Generic Drugmaker Sandoz’s Shares Fall After Sales Outlook Lowered - Regional Media News
4 Articles
4 Articles
The Swiss pharmacist Sandoz Group cut off its revenue expansion perspective this year on Wednesday (28). Exclusive material for subscribers. To have full access, access the link of the subject and register.
The Basel specialist of substitute medicines sees its expansion slowed down by the German market and the persistent turbulence in antibiotics. North America remains the main engine of growthSandoz moderates its growth prospects for the current year, after the third quarter, in a range of 5% to 6%, compared with 5% to 9% previously. The bar for the adjusted gross operating margin (Ebitda), on the other hand, is raised between 23.0% and 23.5%, com…
Generic drugmaker Sandoz’s shares fall after sales outlook lowered - Regional Media News
ZURICH, Oct 28 (Reuters) - Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on third-quarter results, sending shares down over 5% in early trading. The company now expects net [...]
Sandoz continued to grow in the first nine months of the year, with the generic specialist putting more into the higher-margin biosimilar business, especially while the generics division took over.
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
